21 Einträge gefunden

1. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma

   1. Facon, Thierry
   2. Kumar, Shaji K
   3. Plesner, Torben
   4. Orlowski, Robert Z
   5. Moreau, Philippe
   6. Bahlis, Nizar
   7. Basu, Supratik

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

   1. Ludwig, Heinz
   2. Terpos, Evangelos
   3. van de Donk, Niels
   4. Mateos, Maria-Victoria
   5. Moreau, Philippe
   6. Dimopoulos, Melitios-Athanasios
   7. Delforge, Michel

   2023 - Forschungsinformationssystem des UKE
3. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA

   1. Cavo, Michele
   2. San-Miguel, Jesus F F
   3. Usmani, Saad Z
   4. Weisel, Katja C
   5. Dimopoulos, Meletios A A
   6. Avet-Loiseau, Hervé
   7. Paiva, Bruno

   2022 - Forschungsinformationssystem des UKE
4. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

   1. Richardson, Paul G
   2. Schjesvold, Fredrik
   3. Weisel, Katja
   4. Moreau, Philippe
   5. Anderson, Larry D
   6. White, Darrell
   7. Rodriguez-Otero, Paula

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

   1. Facon, Thierry
   2. Kumar, Shaji K
   3. Plesner, Torben
   4. Orlowski, Robert Z
   5. Moreau, Philippe
   6. Bahlis, Nizar
   7. Basu, Supratik

   2021 - Forschungsinformationssystem des UKE
6. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

   1. Ludwig, Heinz
   2. Sonneveld, Pieter
   3. Facon, Thierry
   4. San-Miguel, Jesus
   5. Avet-Loiseau, Hervé
   6. Mohty, Mohamad
   7. Mateos, Maria-Victoria

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

   1. Moreau, Philippe
   2. Hebraud, Benjamin
   3. Facon, Thierry
   4. Leleu, Xavier
   5. Hulin, Cyrille
   6. Hashim, Mahmoud
   7. Hu, Yannan

   2021 - Forschungsinformationssystem des UKE
8. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

   1. Moreau, Philippe
   2. Kumar, Shaji K
   3. San Miguel, Jesús
   4. Davies, Faith
   5. Zamagni, Elena
   6. Bahlis, Nizar
   7. Ludwig, Heinz

   2021 - Forschungsinformationssystem des UKE
9. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

   1. Munshi, Nikhil C
   2. Anderson, Larry D
   3. Shah, Nina
   4. Madduri, Deepu
   5. Berdeja, Jesús
   6. Lonial, Sagar
   7. Raje, Noopur

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
10. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

    1. Avet-Loiseau, Hervé
    2. San-Miguel, Jesus
    3. Casneuf, Tineke
    4. Iida, Shinsuke
    5. Lonial, Sagar
    6. Usmani, Saad Z
    7. Spencer, Andrew

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
11. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

    1. Ludwig, Heinz
    2. Boccadoro, Mario
    3. Moreau, Philippe
    4. San-Miguel, Jesus
    5. Cavo, Michele
    6. Pawlyn, Charlotte
    7. Zweegman, Sonja

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
12. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    1. Dimopoulos, Meletios
    2. Weisel, Katja
    3. Moreau, Philippe
    4. Anderson, Larry D
    5. White, Darrell
    6. San-Miguel, Jesus
    7. Sonneveld, Pieter

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
13. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

    1. Weisel, Katja
    2. Mateos, Maria-Victoria
    3. Gay, Francesca
    4. Delforge, Michel
    5. Cook, Gordon
    6. Szabo, Zsolt
    7. Desgraz, Renaud

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
14. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    1. Dimopoulos, Meletios A
    2. Lonial, Sagar
    3. White, Darrell
    4. Moreau, Philippe
    5. Weisel, Katja
    6. San-Miguel, Jesus
    7. Shpilberg, Ofer

    2020 - Forschungsinformationssystem des UKE
15. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

    1. Dimopoulos, Meletios A
    2. Niesvizky, Ruben
    3. Weisel, Katja
    4. Siegel, David S
    5. Hajek, Roman
    6. Mateos, María-Victoria
    7. Cavo, Michele

    2020 - Forschungsinformationssystem des UKE
16. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

    1. Weisel, Katja
    2. Dimopoulos, Meletios
    3. Moreau, Philippe
    4. Yagci, Munci
    5. Larocca, Alessandra
    6. Kanate, Abraham S
    7. Vural, Filiz

    2020 - Forschungsinformationssystem des UKE
17. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

    1. Goldschmidt, Hartmut
    2. Dimopoulos, Meletios A
    3. Rajkumar, S Vincent
    4. Weisel, Katja C
    5. Moreau, Philippe
    6. Chng, Wee-Joo
    7. Mikala, Gábor

    2020 - Forschungsinformationssystem des UKE
18. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    1. Facon, Thierry
    2. Kumar, Shaji
    3. Plesner, Torben
    4. Orlowski, Robert Z
    5. Moreau, Philippe
    6. Bahlis, Nizar
    7. Basu, Supratik

    2019 - Forschungsinformationssystem des UKE
19. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

    1. Chari, Ajai
    2. Vogl, Dan T
    3. Gavriatopoulou, Maria
    4. Nooka, Ajay K
    5. Yee, Andrew J
    6. Huff, Carol A
    7. Moreau, Philippe

    2019 - Forschungsinformationssystem des UKE
20. How to manage neutropenia in multiple myeloma.

    1. Palumbo, Antonio
    2. Bladé, Jon
    3. Boccadoro, Mario
    4. Palladino, Carmela
    5. Davies, Faith
    6. Dimopoulos, Meletios
    7. Dmoszynska, Anna

    2012 - Forschungsinformationssystem des UKE